

## risperidone to end January 2009

			<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
Case Count			<b>985</b>	<b>31</b>	<b>658</b>
<b>Medicine</b>	<b>Reaction Count</b>	<b>Blood and lymphatic system disorders</b>	<b>Iron deficiency anaemia</b>	<b>1</b>	<b>0</b>
			<b>Anaemia</b>	<b>7</b>	<b>0</b>
			<b>Pancytopenia</b>	<b>6</b>	<b>0</b>
			<b>Thrombocythaemia</b>	<b>1</b>	<b>0</b>
			<b>Thrombocytopenia</b>	<b>7</b>	<b>2</b>
			<b>Lymphadenopathy</b>	<b>2</b>	<b>0</b>
			<b>Eosinophilia</b>	<b>3</b>	<b>0</b>
			<b>Leukocytosis</b>	<b>8</b>	<b>0</b>
			<b>Leukopenia</b>	<b>6</b>	<b>1</b>
			<b>Lymphopenia</b>	<b>1</b>	<b>0</b>
			<b>Agranulocytosis</b>	<b>6</b>	<b>0</b>
			<b>Febrile neutropenia</b>	<b>1</b>	<b>0</b>
			<b>Neutropenia</b>	<b>20</b>	<b>0</b>
			<b>Blood and lymphatic system disorders</b>	<b>69</b>	<b>3</b>
		<b>Cardiac disorders</b>	<b>Atrioventricular block</b>	<b>3</b>	<b>0</b>
			<b>Arrhythmia</b>	<b>4</b>	<b>0</b>
			<b>Bradycardia</b>	<b>6</b>	<b>0</b>
			<b>Tachycardia</b>	<b>15</b>	<b>0</b>
			<b>Atrial fibrillation</b>	<b>1</b>	<b>1</b>
			<b>Supraventricular tachycardia</b>	<b>4</b>	<b>0</b>
			<b>Cardiac arrest</b>	<b>5</b>	<b>3</b>
			<b>Ventricular fibrillation</b>	<b>1</b>	<b>0</b>
			<b>Palpitations</b>	<b>2</b>	<b>0</b>
			<b>Angina pectoris</b>	<b>1</b>	<b>0</b>
			<b>Myocardial infarction</b>	<b>6</b>	<b>2</b>
			<b>Cardiac failure</b>	<b>1</b>	<b>0</b>
			<b>Cardiac failure congestive</b>	<b>1</b>	<b>1</b>
			<b>Left ventricular failure</b>	<b>1</b>	<b>1</b>
			<b>Cardiomyopathy</b>	<b>3</b>	<b>0</b>
			<b>Cardiomegaly</b>	<b>1</b>	<b>1</b>
			<b>Myocarditis</b>	<b>3</b>	<b>0</b>
			<b>Pericarditis</b>	<b>2</b>	<b>0</b>
			<b>Cardiac disorders</b>	<b>60</b>	<b>9</b>
		<b>Congenital, familial and genetic disorders</b>	<b>Deafness congenital</b>	<b>1</b>	<b>0</b>
			<b>Cleft palate</b>	<b>2</b>	<b>0</b>
			<b>Cerebral palsy</b>	<b>1</b>	<b>0</b>
			<b>Tourette's disorder</b>	<b>1</b>	<b>0</b>
			<b>Congenital, familial and genetic disorders</b>	<b>5</b>	<b>0</b>
		<b>Ear and labyrinth disorders</b>	<b>Hyperacusis</b>	<b>1</b>	<b>0</b>
			<b>Ear and labyrinth disorders</b>	<b>1</b>	<b>0</b>
		<b>Endocrine disorders</b>	<b>Hyperprolactinaemia</b>	<b>50</b>	<b>0</b>

## **risperidone to end January 2009**

<b>Medicine</b>	<b>Reaction Count</b>		<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		<b>Endocrine disorders</b>	<b>Diabetes insipidus</b>	<b>1</b>	<b>0</b>
			<b>Inappropriate antidiuretic hormone secretion</b>	<b>2</b>	<b>0</b>
			<b>Goitre</b>	<b>1</b>	<b>0</b>
			<b>Hyperthyroidism</b>	<b>1</b>	<b>0</b>
			<b>Hypothyroidism</b>	<b>2</b>	<b>0</b>
			<b>Endocrine disorders</b>	<b>57</b>	<b>0</b>
		<b>Eye disorders</b>	<b>Lacrimation increased</b>	<b>1</b>	<b>0</b>
			<b>Eye oedema</b>	<b>1</b>	<b>0</b>
			<b>Eye pain</b>	<b>1</b>	<b>0</b>
			<b>Retinal disorder</b>	<b>1</b>	<b>0</b>
			<b>Glaucoma</b>	<b>1</b>	<b>0</b>
			<b>Conjunctivitis</b>	<b>1</b>	<b>0</b>
			<b>Eyelid oedema</b>	<b>1</b>	<b>0</b>
			<b>Ocular hyperaemia</b>	<b>1</b>	<b>0</b>
			<b>Blepharospasm</b>	<b>5</b>	<b>0</b>
			<b>Eyelid ptosis</b>	<b>1</b>	<b>0</b>
			<b>Oculogyric crisis</b>	<b>8</b>	<b>0</b>
			<b>Eye rolling</b>	<b>1</b>	<b>0</b>
			<b>Papilloedema</b>	<b>1</b>	<b>0</b>
			<b>Macular degeneration</b>	<b>1</b>	<b>0</b>
			<b>Retinal haemorrhage</b>	<b>1</b>	<b>0</b>
			<b>Retinopathy</b>	<b>1</b>	<b>0</b>
			<b>Visual acuity reduced</b>	<b>1</b>	<b>0</b>
			<b>Myopia</b>	<b>1</b>	<b>0</b>
			<b>Diplopia</b>	<b>1</b>	<b>0</b>
			<b>Vision blurred</b>	<b>10</b>	<b>0</b>
			<b>Visual impairment</b>	<b>4</b>	<b>0</b>
			<b>Eye disorders</b>	<b>44</b>	<b>0</b>
		<b>Gastrointestinal disorders</b>	<b>Gingivitis</b>	<b>1</b>	<b>0</b>
			<b>Pancreatitis</b>	<b>2</b>	<b>0</b>
			<b>Gastrointestinal disorder</b>	<b>2</b>	<b>0</b>
			<b>Haematemesis</b>	<b>1</b>	<b>0</b>
			<b>Haematochezia</b>	<b>1</b>	<b>0</b>
			<b>Diarrhoea</b>	<b>2</b>	<b>0</b>
			<b>Constipation</b>	<b>9</b>	<b>0</b>
			<b>Abdominal distension</b>	<b>3</b>	<b>0</b>
			<b>Flatulence</b>	<b>1</b>	<b>0</b>
			<b>Abdominal pain</b>	<b>6</b>	<b>0</b>
			<b>Abdominal pain upper</b>	<b>2</b>	<b>0</b>
			<b>Breath odour</b>	<b>1</b>	<b>0</b>
			<b>Dysphagia</b>	<b>18</b>	<b>1</b>
			<b>Faecal incontinence</b>	<b>3</b>	<b>0</b>

## **risperidone to end January 2009**

<b>Medicine</b>	<b>Reaction Count</b>		<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		<b>Gastrointestinal disorders</b>	<b>Nausea</b>	<b>12</b>	<b>0</b>
			<b>Vomiting</b>	<b>14</b>	<b>0</b>
			<b>Intestinal obstruction</b>	<b>2</b>	<b>0</b>
			<b>Duodenal ulcer haemorrhage</b>	<b>1</b>	<b>0</b>
			<b>Thrombosis mesenteric vessel</b>	<b>1</b>	<b>0</b>
			<b>Lip oedema</b>	<b>2</b>	<b>0</b>
			<b>Lip swelling</b>	<b>1</b>	<b>0</b>
			<b>Oral mucosal eruption</b>	<b>1</b>	<b>0</b>
			<b>Retroperitoneal fibrosis</b>	<b>1</b>	<b>0</b>
			<b>Dry mouth</b>	<b>5</b>	<b>2</b>
			<b>Saliva altered</b>	<b>1</b>	<b>0</b>
			<b>Salivary hypersecretion</b>	<b>14</b>	<b>0</b>
			<b>Salivary gland enlargement</b>	<b>1</b>	<b>0</b>
			<b>Swollen tongue</b>	<b>5</b>	<b>5</b>
			<b>Tongue oedema</b>	<b>6</b>	<b>0</b>
			<b>Tongue spasm</b>	<b>2</b>	<b>2</b>
			<b>Gastrointestinal disorders</b>	<b>121</b>	<b>1</b>
					<b>78</b>
		<b>General disorders and administration site conditions</b>	<b>Injection site mass</b>	<b>1</b>	<b>0</b>
			<b>Injection site pain</b>	<b>2</b>	<b>0</b>
			<b>Injection site reaction</b>	<b>2</b>	<b>0</b>
			<b>Hyperthermia malignant</b>	<b>2</b>	<b>0</b>
			<b>Hypothermia</b>	<b>3</b>	<b>2</b>
			<b>Pyrexia</b>	<b>38</b>	<b>1</b>
			<b>Death</b>	<b>6</b>	<b>5</b>
			<b>Sudden death</b>	<b>3</b>	<b>3</b>
			<b>Asthenia</b>	<b>6</b>	<b>0</b>
			<b>Fatigue</b>	<b>15</b>	<b>0</b>
			<b>Malaise</b>	<b>7</b>	<b>0</b>
			<b>Abasia</b>	<b>2</b>	<b>0</b>
			<b>Gait disturbance</b>	<b>13</b>	<b>0</b>
			<b>Condition aggravated</b>	<b>1</b>	<b>0</b>
			<b>Exercise tolerance decreased</b>	<b>1</b>	<b>0</b>
			<b>Influenza like illness</b>	<b>6</b>	<b>0</b>
			<b>Irritability</b>	<b>1</b>	<b>0</b>
			<b>Mucosal inflammation</b>	<b>1</b>	<b>0</b>
			<b>Face oedema</b>	<b>12</b>	<b>0</b>
			<b>Gravitational oedema</b>	<b>3</b>	<b>0</b>
			<b>Oedema</b>	<b>4</b>	<b>1</b>
			<b>Oedema peripheral</b>	<b>9</b>	<b>9</b>
			<b>Chest pain</b>	<b>5</b>	<b>3</b>
			<b>Pain</b>	<b>1</b>	<b>1</b>
			<b>Chest discomfort</b>	<b>2</b>	<b>2</b>

## risperidone to end January 2009

<b>Medicine</b>	<b>Reaction Count</b>		<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		<b>General disorders and administration site conditions</b>	<b>Chills</b>	<b>3</b>	<b>0</b>
			<b>Feeling abnormal</b>	<b>5</b>	<b>0</b>
			<b>Feeling jittery</b>	<b>2</b>	<b>0</b>
			<b>Thirst</b>	<b>3</b>	<b>0</b>
			<b>Drug interaction</b>	<b>3</b>	<b>0</b>
			<b>Food interaction</b>	<b>1</b>	<b>0</b>
			<b>Drug ineffective</b>	<b>13</b>	<b>0</b>
			<b>Therapeutic response decreased</b>	<b>4</b>	<b>0</b>
			<b>Drug withdrawal syndrome</b>	<b>3</b>	<b>0</b>
			<b>Drug withdrawal syndrome neonatal</b>	<b>4</b>	<b>0</b>
			<b>General disorders and administration site conditions</b>	<b>187</b>	<b>9</b>
		<b>Hepatobiliary disorders</b>	<b>Bile duct obstruction</b>	<b>1</b>	<b>0</b>
			<b>Gallbladder disorder</b>	<b>1</b>	<b>0</b>
			<b>Hepatitis cholestatic</b>	<b>1</b>	<b>0</b>
			<b>Jaundice</b>	<b>2</b>	<b>0</b>
			<b>Hepatic function abnormal</b>	<b>26</b>	<b>1</b>
			<b>Hepatomegaly</b>	<b>1</b>	<b>0</b>
			<b>Hepatic steatosis</b>	<b>1</b>	<b>1</b>
			<b>Hepatitis</b>	<b>5</b>	<b>0</b>
			<b>Hepatobiliary disorders</b>	<b>38</b>	<b>2</b>
		<b>Immune system disorders</b>	<b>Hypersensitivity</b>	<b>3</b>	<b>0</b>
			<b>Anaphylactoid reaction</b>	<b>1</b>	<b>0</b>
			<b>Immune system disorders</b>	<b>4</b>	<b>0</b>
		<b>Infections and infestations</b>	<b>Cellulitis</b>	<b>1</b>	<b>0</b>
			<b>Appendicitis</b>	<b>1</b>	<b>0</b>
			<b>Mastitis</b>	<b>1</b>	<b>0</b>
			<b>Hepatic infection</b>	<b>1</b>	<b>0</b>
			<b>Abscess</b>	<b>2</b>	<b>0</b>
			<b>Infection</b>	<b>3</b>	<b>0</b>
			<b>Lower respiratory tract infection</b>	<b>1</b>	<b>0</b>
			<b>Pneumonia</b>	<b>3</b>	<b>2</b>
			<b>Sepsis</b>	<b>3</b>	<b>1</b>
			<b>Pharyngitis</b>	<b>3</b>	<b>0</b>
			<b>Rhinitis</b>	<b>2</b>	<b>0</b>
			<b>Kidney infection</b>	<b>1</b>	<b>0</b>
			<b>Herpes zoster</b>	<b>1</b>	<b>0</b>
			<b>Infections and infestations</b>	<b>23</b>	<b>3</b>
		<b>Injury, poisoning and procedural complications</b>	<b>Drug toxicity</b>	<b>1</b>	<b>1</b>
			<b>Therapeutic agent toxicity</b>	<b>1</b>	<b>0</b>
			<b>Drug exposure during pregnancy</b>	<b>7</b>	<b>0</b>
			<b>Subdural haematoma</b>	<b>1</b>	<b>0</b>
			<b>Muscle injury</b>	<b>1</b>	<b>1</b>

## **risperidone to end January 2009**

Medicine	Reaction Count		Case Group	Death Outcomes	Sole
		Injury, poisoning and procedural complications	Tendon injury	1	0
			Fall	11	1
			Drug administration error	1	0
			Incorrect dose administered	1	1
			Incorrect route of drug administration	1	0
			Medication error	3	0
			Intentional overdose	1	0
			Overdose	6	1
			Injury, poisoning and procedural complications	36	4
		Investigations	Ejection fraction decreased	1	0
			Electrocardiogram QT prolonged	8	0
			Electrocardiogram T wave inversion	2	0
			Electrocardiogram abnormal	2	0
			Heart rate abnormal	1	0
			Heart rate increased	1	0
			Heart rate irregular	1	0
			Blood pressure decreased	1	0
			Blood pressure increased	1	0
			Blood prolactin increased	20	0
			Blood prolactin	1	0
			Blood testosterone decreased	1	0
			Blood testosterone increased	1	0
			Blood creatine phosphokinase increased	44	2
			Troponin increased	1	0
			Blood lactate dehydrogenase increased	1	0
			Prothrombin level increased	1	0
			Red blood cell sedimentation rate increased	2	0
			Neutrophil count decreased	1	0
			Alanine aminotransferase increased	2	0
			Aspartate aminotransferase increased	1	0
			Hepatic enzyme increased	3	0
			Liver function test abnormal	6	0
			Antiphospholipid antibodies positive	1	0
			Blood triglycerides increased	1	0
			Oxygen saturation decreased	1	0
			Blood glucose fluctuation	1	0
			Blood glucose increased	2	0
			Electroencephalogram abnormal	1	0
			Body temperature fluctuation	1	0
			Weight decreased	5	0
			Weight increased	50	0

## **risperidone to end January 2009**

Medicine	Reaction Count	Investigations	Case Group	Death Outcomes	Sole
		<b>Sperm count abnormal</b>	1	0	1
		<b>Drug level above therapeutic</b>	1	0	0
		<b>Drug level increased</b>	2	1	0
		<b>Investigations</b>	<b>170</b>	<b>3</b>	<b>106</b>
		<b>Metabolism and nutrition disorders</b>			
		<b>Metabolic acidosis</b>	1	0	0
		<b>Anorexia</b>	6	0	4
		<b>Hypophagia</b>	1	0	0
		<b>Increased appetite</b>	7	0	6
		<b>Obesity</b>	1	0	1
		<b>Hypercalcaemia</b>	1	1	0
		<b>Hypomagnesaemia</b>	1	1	0
		<b>Diabetic ketoacidosis</b>	1	0	0
		<b>Hypochloraemia</b>	1	1	0
		<b>Polydipsia</b>	4	0	2
		<b>Hyperkalaemia</b>	1	0	1
		<b>Hypokalaemia</b>	1	0	0
		<b>Hypernatraemia</b>	1	0	0
		<b>Hyponatraemia</b>	12	1	5
		<b>Dehydration</b>	3	1	2
		<b>Diabetes mellitus</b>	9	0	6
		<b>Gestational diabetes</b>	1	0	1
		<b>Type 2 diabetes mellitus</b>	2	0	1
		<b>Glucose tolerance impaired</b>	1	0	1
		<b>Hyperglycaemia</b>	5	0	0
		<b>Hypoglycaemia</b>	2	0	0
		<b>Hypertriglyceridaemia</b>	1	0	1
		<b>Hyperproteinaemia</b>	1	0	1
		<b>Hypoproteinaemia</b>	2	0	1
		<b>Gout</b>	1	0	0
		<b>Vitamin B12 deficiency</b>	1	0	1
		<b>Metabolism and nutrition disorders</b>	<b>68</b>	<b>5</b>	<b>34</b>
		<b>Musculoskeletal and connective tissue disorders</b>			
		<b>Jaw disorder</b>	1	0	1
		<b>Systemic lupus erythematosus</b>	1	0	1
		<b>Synostosis</b>	1	0	1
		<b>Arthritis</b>	1	0	0
		<b>Arthralgia</b>	1	0	0
		<b>Joint stiffness</b>	4	0	2
		<b>Joint swelling</b>	1	0	1
		<b>Rheumatoid arthritis</b>	1	0	1
		<b>Myositis</b>	1	0	1
		<b>Myalgia</b>	8	0	3
		<b>Muscle disorder</b>	1	0	1

## **risperidone to end January 2009**

<b>Medicine</b>	<b>Reaction Count</b>		<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		<b>Musculoskeletal and connective tissue disorders</b>	<b>Muscle spasms</b>	<b>10</b>	<b>0</b>
			<b>Muscle twitching</b>	<b>5</b>	<b>0</b>
			<b>Muscle rigidity</b>	<b>14</b>	<b>0</b>
			<b>Nuchal rigidity</b>	<b>1</b>	<b>0</b>
			<b>Torticollis</b>	<b>3</b>	<b>0</b>
			<b>Trismus</b>	<b>3</b>	<b>0</b>
			<b>Muscular weakness</b>	<b>3</b>	<b>0</b>
			<b>Myopathy</b>	<b>2</b>	<b>0</b>
			<b>Rhabdomyolysis</b>	<b>4</b>	<b>0</b>
			<b>Mastication disorder</b>	<b>1</b>	<b>0</b>
			<b>Mobility decreased</b>	<b>6</b>	<b>0</b>
			<b>Muscle contracture</b>	<b>2</b>	<b>0</b>
			<b>Musculoskeletal stiffness</b>	<b>21</b>	<b>0</b>
			<b>Posture abnormal</b>	<b>1</b>	<b>0</b>
			<b>Back pain</b>	<b>5</b>	<b>0</b>
			<b>Flank pain</b>	<b>1</b>	<b>0</b>
			<b>Pain in extremity</b>	<b>5</b>	<b>0</b>
			<b>Musculoskeletal and connective tissue disorders</b>	<b>108</b>	<b>0</b>
		<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>	<b>Breast cancer</b>	<b>1</b>	<b>0</b>
			<b>Breast cancer female</b>	<b>6</b>	<b>0</b>
			<b>Breast cancer male</b>	<b>1</b>	<b>0</b>
			<b>Pituitary tumour benign</b>	<b>2</b>	<b>0</b>
			<b>Pituitary tumour</b>	<b>1</b>	<b>0</b>
			<b>Lip neoplasm</b>	<b>1</b>	<b>0</b>
			<b>Hairy cell leukaemia</b>	<b>1</b>	<b>0</b>
			<b>Metastases to lung</b>	<b>1</b>	<b>0</b>
			<b>Squamous cell carcinoma</b>	<b>1</b>	<b>0</b>
			<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>	<b>15</b>	<b>0</b>
		<b>Nervous system disorders</b>	<b>Cerebrovascular accident</b>	<b>14</b>	<b>3</b>
			<b>Cerebrovascular disorder</b>	<b>2</b>	<b>0</b>
			<b>Cranial nerve disorder</b>	<b>1</b>	<b>0</b>
			<b>Facial palsy</b>	<b>1</b>	<b>0</b>
			<b>Tongue paralysis</b>	<b>2</b>	<b>0</b>
			<b>Encephalopathy</b>	<b>1</b>	<b>0</b>
			<b>Toxic encephalopathy</b>	<b>1</b>	<b>0</b>
			<b>Headache</b>	<b>18</b>	<b>0</b>
			<b>Migraine</b>	<b>2</b>	<b>0</b>
			<b>Migraine with aura</b>	<b>1</b>	<b>0</b>
			<b>Intracranial pressure increased</b>	<b>2</b>	<b>0</b>
			<b>Dementia</b>	<b>3</b>	<b>0</b>
			<b>Amnesia</b>	<b>7</b>	<b>0</b>

## **risperidone to end January 2009**

<b>Medicine</b>	<b>Reaction Count</b>	<b>Nervous system disorders</b>	<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		Disturbance in attention	1	0	0
		Choreoathetosis	1	0	1
		Akathisia	25	0	16
		Bradykinesia	1	0	0
		Dyskinesia	17	1	12
		Extrapyramidal disorder	47	0	34
		Hyperkinesia	13	0	9
		Hypokinesia	7	0	6
		Movement disorder	1	0	0
		Tardive dyskinesia	38	0	30
		Dystonia	54	0	34
		Opisthotonus	3	0	2
		Cogwheel rigidity	11	0	5
		Masked facies	2	0	1
		Parkinsonian gait	2	0	1
		Parkinsonism	13	1	7
		Tremor	31	0	14
		Hyperreflexia	2	0	0
		Hyporeflexia	1	0	0
		Ataxia	5	0	4
		Balance disorder	4	0	4
		Coordination abnormal	2	0	1
		Coma	2	0	0
		Aphasia	2	0	1
		Consciousness fluctuating	11	1	8
		Depressed level of consciousness	3	1	2
		Lethargy	5	0	3
		Loss of consciousness	1	0	1
		Sedation	7	1	4
		Somnolence	17	0	12
		Stupor	2	1	1
		Syncope	7	0	7
		Clonus	2	0	0
		Dizziness	24	0	14
		Drooling	4	0	3
		Meningism	1	0	1
		Myoclonus	3	0	1
		Crying	1	0	1
		Paraesthesia	2	0	2
		Ageusia	1	0	1
		Hypoesthesia	4	0	3
		Restless legs syndrome	3	0	2

## **risperidone to end January 2009**

<b>Medicine</b>	<b>Reaction Count</b>		<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		<b>Nervous system disorders</b>	<b>Sensory disturbance</b>	<b>2</b>	<b>0</b>
			<b>Dysarthria</b>	<b>12</b>	<b>0</b>
			<b>Dysphasia</b>	<b>1</b>	<b>0</b>
			<b>Speech disorder</b>	<b>7</b>	<b>0</b>
			<b>Drop attacks</b>	<b>1</b>	<b>0</b>
			<b>Hypertonia</b>	<b>33</b>	<b>2</b>
			<b>Hypotonia</b>	<b>1</b>	<b>0</b>
			<b>Neuroleptic malignant syndrome</b>	<b>53</b>	<b>2</b>
			<b>Serotonin syndrome</b>	<b>1</b>	<b>0</b>
			<b>Neuropathy peripheral</b>	<b>2</b>	<b>0</b>
			<b>Grand mal convulsion</b>	<b>5</b>	<b>0</b>
			<b>Simple partial seizures</b>	<b>1</b>	<b>0</b>
			<b>Convulsion</b>	<b>25</b>	<b>1</b>
			<b>Partial seizures with secondary generalisation</b>	<b>1</b>	<b>0</b>
			<b>Sleep phase rhythm disturbance</b>	<b>1</b>	<b>0</b>
			<b>Nervous system disorders</b>	<b>584</b>	<b>14</b>
					<b>365</b>
		<b>Pregnancy, puerperium and perinatal conditions</b>	<b>Abortion spontaneous</b>	<b>4</b>	<b>0</b>
			<b>Foetal hypokinesia</b>	<b>1</b>	<b>0</b>
			<b>Ectopic pregnancy</b>	<b>1</b>	<b>0</b>
			<b>Premature baby</b>	<b>2</b>	<b>0</b>
			<b>Small for dates baby</b>	<b>1</b>	<b>0</b>
			<b>Neonatal disorder</b>	<b>1</b>	<b>0</b>
			<b>Pregnancy, puerperium and perinatal conditions</b>	<b>10</b>	<b>0</b>
					<b>2</b>
		<b>Psychiatric disorders</b>	<b>Agitation</b>	<b>25</b>	<b>1</b>
			<b>Anxiety</b>	<b>17</b>	<b>0</b>
			<b>Nervousness</b>	<b>1</b>	<b>0</b>
			<b>Neurosis</b>	<b>1</b>	<b>0</b>
			<b>Obsessive-compulsive disorder</b>	<b>2</b>	<b>0</b>
			<b>Catatonia</b>	<b>3</b>	<b>0</b>
			<b>Restlessness</b>	<b>8</b>	<b>0</b>
			<b>Tic</b>	<b>2</b>	<b>0</b>
			<b>Mutism</b>	<b>1</b>	<b>0</b>
			<b>Dysphemia</b>	<b>2</b>	<b>0</b>
			<b>Confusional state</b>	<b>29</b>	<b>1</b>
			<b>Disorientation</b>	<b>1</b>	<b>0</b>
			<b>Delirium</b>	<b>9</b>	<b>1</b>
			<b>Depression</b>	<b>7</b>	<b>0</b>
			<b>Depressed mood</b>	<b>5</b>	<b>0</b>
			<b>Depressive symptom</b>	<b>1</b>	<b>0</b>
			<b>Depersonalisation</b>	<b>3</b>	<b>0</b>
			<b>Delusion</b>	<b>7</b>	<b>0</b>

## **risperidone to end January 2009**

<b>Medicine</b>	<b>Reaction Count</b>	<b>Psychiatric disorders</b>	<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		Hallucination	12	0	8
		Hallucination, auditory	1	0	1
		Hallucination, visual	1	0	1
		Thinking abnormal	6	0	3
		Hypomania	1	0	0
		Mania	2	0	0
		Affect lability	2	0	1
		Flat affect	3	0	3
		Anger	3	0	2
		Elevated mood	1	0	0
		Emotional distress	1	0	1
		Euphoric mood	1	0	1
		Frustration	1	0	0
		Mood swings	1	0	1
		Apathy	1	0	1
		Aggression	16	0	11
		Disinhibition	1	0	0
		Homicidal ideation	5	0	1
		Paranoia	2	0	2
		Personality change	1	0	1
		Social avoidant behaviour	1	0	1
		Violence-related symptom	1	0	0
		Abnormal behaviour	2	1	0
		Staring	1	0	0
		Mental disorder	2	0	0
		Alcohol abuse	1	0	1
		Intentional drug misuse	1	0	1
		Withdrawal syndrome	5	0	5
		Psychotic disorder	10	0	6
		Schizophrenia	1	0	1
		Anorgasmia	1	0	1
		Libido decreased	1	0	1
		Loss of libido	2	0	2
		Insomnia	15	0	9
		Abnormal dreams	1	0	1
		Nightmare	3	0	1
		Sleep disorder	1	0	0
		Completed suicide	5	5	3
		Self injurious behaviour	2	0	1
		Suicidal ideation	17	0	9
		Suicide attempt	8	0	3
		Psychiatric disorders	267	9	162

## **risperidone to end January 2009**

<b>Medicine</b>	<b>Reaction Count</b>		<b>Case Group</b>	<b>Death Outcomes</b>	<b>Sole</b>
		<b>Renal and urinary disorders</b>	<b>Tubulointerstitial nephritis</b>	<b>1</b>	<b>0</b>
			<b>Renal failure</b>	<b>1</b>	<b>0</b>
			<b>Renal failure acute</b>	<b>4</b>	<b>0</b>
			<b>Renal impairment</b>	<b>6</b>	<b>1</b>
			<b>Dysuria</b>	<b>1</b>	<b>0</b>
			<b>Incontinence</b>	<b>1</b>	<b>0</b>
			<b>Micturition disorder</b>	<b>1</b>	<b>0</b>
			<b>Pollakiuria</b>	<b>1</b>	<b>0</b>
			<b>Urinary incontinence</b>	<b>13</b>	<b>0</b>
			<b>Urinary retention</b>	<b>3</b>	<b>0</b>
			<b>Glycosuria</b>	<b>1</b>	<b>0</b>
			<b>Haematuria</b>	<b>1</b>	<b>0</b>
			<b>Ketonuria</b>	<b>1</b>	<b>0</b>
			<b>Myoglobinuria</b>	<b>1</b>	<b>0</b>
			<b>Polyuria</b>	<b>2</b>	<b>0</b>
			<b>Nephrolithiasis</b>	<b>1</b>	<b>0</b>
			<b>Renal and urinary disorders</b>	<b>39</b>	<b>1</b>
		<b>Reproductive system and breast disorders</b>	<b>Breast enlargement</b>	<b>4</b>	<b>0</b>
			<b>Breast mass</b>	<b>1</b>	<b>0</b>
			<b>Gynaecomastia</b>	<b>8</b>	<b>0</b>
			<b>Breast discharge</b>	<b>1</b>	<b>0</b>
			<b>Breast engorgement</b>	<b>1</b>	<b>0</b>
			<b>Breast pain</b>	<b>6</b>	<b>0</b>
			<b>Breast tenderness</b>	<b>1</b>	<b>0</b>
			<b>Nipple exudate bloody</b>	<b>1</b>	<b>0</b>
			<b>Galactorrhoea</b>	<b>35</b>	<b>0</b>
			<b>Lactation disorder</b>	<b>2</b>	<b>0</b>
			<b>Menstrual disorder</b>	<b>4</b>	<b>0</b>
			<b>Menstruation irregular</b>	<b>2</b>	<b>0</b>
			<b>Metrorrhagia</b>	<b>1</b>	<b>0</b>
			<b>Amenorrhoea</b>	<b>23</b>	<b>0</b>
			<b>Menorrhagia</b>	<b>1</b>	<b>0</b>
			<b>Polycystic ovaries</b>	<b>1</b>	<b>0</b>
			<b>Genital ulceration</b>	<b>1</b>	<b>0</b>
			<b>Oedema genital</b>	<b>1</b>	<b>0</b>
			<b>Ejaculation disorder</b>	<b>1</b>	<b>0</b>
			<b>Ejaculation failure</b>	<b>8</b>	<b>0</b>
			<b>Erectile dysfunction</b>	<b>5</b>	<b>0</b>
			<b>Priapism</b>	<b>9</b>	<b>0</b>
			<b>Infertility</b>	<b>2</b>	<b>0</b>
			<b>Sexual dysfunction</b>	<b>3</b>	<b>0</b>
			<b>Testicular disorder</b>	<b>2</b>	<b>0</b>

## **risperidone to end January 2009**

Medicine	Reaction Count		Case Group	Death Outcomes	Sole
		<b>Reproductive system and breast disorders</b>	<b>Testicular pain</b>	<b>1</b>	<b>0</b>
			<b>Reproductive system and breast disorders</b>	<b>125</b>	<b>0</b>
		<b>Respiratory, thoracic and mediastinal disorders</b>	<b>Bronchospasm</b>	<b>2</b>	<b>0</b>
			<b>Wheezing</b>	<b>1</b>	<b>0</b>
			<b>Pneumonia aspiration</b>	<b>1</b>	<b>0</b>
			<b>Pulmonary oedema</b>	<b>2</b>	<b>2</b>
			<b>Pulmonary embolism</b>	<b>4</b>	<b>0</b>
			<b>Apnoea</b>	<b>1</b>	<b>0</b>
			<b>Dyspnoea</b>	<b>24</b>	<b>0</b>
			<b>Hyperventilation</b>	<b>1</b>	<b>0</b>
			<b>Hypoventilation</b>	<b>2</b>	<b>0</b>
			<b>Respiratory arrest</b>	<b>1</b>	<b>0</b>
			<b>Respiratory depression</b>	<b>4</b>	<b>0</b>
			<b>Respiratory distress</b>	<b>1</b>	<b>0</b>
			<b>Tachypnoea</b>	<b>1</b>	<b>0</b>
			<b>Haemoptysis</b>	<b>1</b>	<b>0</b>
			<b>Respiratory failure</b>	<b>2</b>	<b>2</b>
			<b>Respiratory disorder</b>	<b>1</b>	<b>0</b>
			<b>Choking</b>	<b>3</b>	<b>0</b>
			<b>Oropharyngeal pain</b>	<b>2</b>	<b>0</b>
			<b>Rhinorrhoea</b>	<b>1</b>	<b>0</b>
			<b>Throat tightness</b>	<b>2</b>	<b>0</b>
			<b>Stridor</b>	<b>1</b>	<b>0</b>
			<b>Nasal congestion</b>	<b>1</b>	<b>0</b>
			<b>Epistaxis</b>	<b>5</b>	<b>0</b>
			<b>Pharyngeal oedema</b>	<b>1</b>	<b>0</b>
			<b>Respiratory, thoracic and mediastinal disorders</b>	<b>65</b>	<b>4</b>
		<b>Skin and subcutaneous tissue disorders</b>	<b>Angioedema</b>	<b>7</b>	<b>0</b>
			<b>Periorbital oedema</b>	<b>6</b>	<b>0</b>
			<b>Urticaria</b>	<b>11</b>	<b>0</b>
			<b>Lichenoid keratosis</b>	<b>1</b>	<b>0</b>
			<b>Skin striae</b>	<b>1</b>	<b>0</b>
			<b>Dermatitis bullous</b>	<b>1</b>	<b>0</b>
			<b>Erythema multiforme</b>	<b>1</b>	<b>0</b>
			<b>Dry skin</b>	<b>2</b>	<b>0</b>
			<b>Skin discolouration</b>	<b>1</b>	<b>0</b>
			<b>Skin disorder</b>	<b>1</b>	<b>0</b>
			<b>Skin odour abnormal</b>	<b>2</b>	<b>0</b>
			<b>Swelling face</b>	<b>4</b>	<b>0</b>
			<b>Dermatitis</b>	<b>1</b>	<b>0</b>
			<b>Eczema</b>	<b>1</b>	<b>0</b>

## **risperidone to end January 2009**

Medicine	Reaction Count		Case Group	Death Outcomes	Sole
		<b>Skin and subcutaneous tissue disorders</b>	<b>Erythema</b>	<b>3</b>	<b>0</b>
			<b>Rash erythematous</b>	<b>4</b>	<b>0</b>
			<b>Skin exfoliation</b>	<b>4</b>	<b>0</b>
			<b>Rash papular</b>	<b>1</b>	<b>0</b>
			<b>Photosensitivity reaction</b>	<b>1</b>	<b>0</b>
			<b>Pruritus</b>	<b>16</b>	<b>0</b>
			<b>Rash pruritic</b>	<b>3</b>	<b>0</b>
			<b>Psoriasis</b>	<b>2</b>	<b>0</b>
			<b>Rash</b>	<b>24</b>	<b>0</b>
			<b>Rash generalised</b>	<b>1</b>	<b>0</b>
			<b>Rash macular</b>	<b>2</b>	<b>0</b>
			<b>Rash maculo-papular</b>	<b>5</b>	<b>0</b>
			<b>Skin hyperpigmentation</b>	<b>1</b>	<b>0</b>
			<b>Skin hypopigmentation</b>	<b>1</b>	<b>0</b>
			<b>Alopecia</b>	<b>5</b>	<b>0</b>
			<b>Cold sweat</b>	<b>1</b>	<b>0</b>
			<b>Hyperhidrosis</b>	<b>7</b>	<b>0</b>
			<b>Hirsutism</b>	<b>1</b>	<b>0</b>
			<b>Hypertrichosis</b>	<b>1</b>	<b>0</b>
			<b>Hair texture abnormal</b>	<b>1</b>	<b>0</b>
			<b>Seborrhoea</b>	<b>1</b>	<b>0</b>
			<b>Purpura</b>	<b>2</b>	<b>0</b>
			<b>Livedo reticularis</b>	<b>1</b>	<b>0</b>
			<b>Skin and subcutaneous tissue disorders</b>	<b>128</b>	<b>0</b>
		<b>Social circumstances</b>	<b>Treatment noncompliance</b>	<b>1</b>	<b>0</b>
			<b>Social circumstances</b>	<b>1</b>	<b>0</b>
		<b>Surgical and medical procedures</b>	<b>Therapy regimen changed</b>	<b>17</b>	<b>0</b>
			<b>Surgical and medical procedures</b>	<b>17</b>	<b>0</b>
		<b>Vascular disorders</b>	<b>Infarction</b>	<b>1</b>	<b>0</b>
			<b>Blood pressure fluctuation</b>	<b>1</b>	<b>0</b>
			<b>Circulatory collapse</b>	<b>8</b>	<b>1</b>
			<b>Hypotension</b>	<b>17</b>	<b>0</b>
			<b>Orthostatic hypotension</b>	<b>15</b>	<b>1</b>
			<b>Thrombosis</b>	<b>1</b>	<b>0</b>
			<b>Deep vein thrombosis</b>	<b>2</b>	<b>0</b>
			<b>Flushing</b>	<b>6</b>	<b>0</b>
			<b>Hot flush</b>	<b>2</b>	<b>0</b>
			<b>Pallor</b>	<b>1</b>	<b>0</b>
			<b>Hypertension</b>	<b>3</b>	<b>0</b>
			<b>Vascular disorders</b>	<b>57</b>	<b>2</b>
		<b>Reaction</b>		<b>2299</b>	<b>69</b>
					<b>1429</b>